{Reference Type}: Journal Article
{Title}: Potential antiprostatic performance of novel lanthanide-complexes based on 5-nitropicolinic acid.
{Author}: García-García A;Cristobal-Cueto P;Hidalgo T;Vitórica-Yrezábal IJ;Rodríguez-Diéguez A;Horcajada P;Rojas S;
{Journal}: J Biol Inorg Chem
{Volume}: 29
{Issue}: 3
{Year}: 2024 04 8
{Factor}: 3.862
{DOI}: 10.1007/s00775-024-02054-0
{Abstract}: Two new lanthanide-complexes based on the 5-nitropicolinate ligand (5-npic) were obtained and fully characterized. Single-crystal X-ray diffraction revealed that these compounds are isostructural to a Dy-complex, previously published by us, based on dinuclear monomers link together with an extended hydrogen bond network, providing a final chemical formula of [Ln2(5-npic)6(H2O)4]·(H2O)2, where Ln = Dy (1), Gd (2), and Tb (3). Preliminary photoluminescent studies exhibited a ligand-centered emission for all complexes. The potential antitumoral activity of these materials was assayed in a prostatic cancer cell line (PC-3; the 2nd most common male cancerous disease), showing a significant anticancer activity (50-60% at 500 μg·mL-1). In turn, a high biocompatibility by both, the complexes and their precursors in human immunological HL-60 cells, was evidenced. In view of the strongest toxic effect in the tumoral cell line provided by the free 5-npic ligand (~ 40-50%), the overall anticancer complex performance seems to be triggered by the presence of this molecule.